CN104582490A - 治疗、诊断和/或监测氧相关疾病进展的方法 - Google Patents

治疗、诊断和/或监测氧相关疾病进展的方法 Download PDF

Info

Publication number
CN104582490A
CN104582490A CN201380043850.3A CN201380043850A CN104582490A CN 104582490 A CN104582490 A CN 104582490A CN 201380043850 A CN201380043850 A CN 201380043850A CN 104582490 A CN104582490 A CN 104582490A
Authority
CN
China
Prior art keywords
oxygen
protectant
relevant disease
methods according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380043850.3A
Other languages
English (en)
Chinese (zh)
Inventor
杰·普拉夫达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104582490A publication Critical patent/CN104582490A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/206664—Ozone or peroxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380043850.3A 2012-07-03 2013-07-02 治疗、诊断和/或监测氧相关疾病进展的方法 Pending CN104582490A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (1)

Publication Number Publication Date
CN104582490A true CN104582490A (zh) 2015-04-29

Family

ID=49882592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380043850.3A Pending CN104582490A (zh) 2012-07-03 2013-07-02 治疗、诊断和/或监测氧相关疾病进展的方法

Country Status (7)

Country Link
US (1) US20150174160A1 (enExample)
EP (1) EP2866565A4 (enExample)
JP (1) JP6509112B2 (enExample)
CN (1) CN104582490A (enExample)
AU (2) AU2013286876B2 (enExample)
CA (1) CA2915793A1 (enExample)
WO (1) WO2014008273A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021522519A (ja) * 2018-04-19 2021-08-30 スティッキーセル ピーティーワイ リミテッドＳｔｉｃｋｙｃｅｌｌ Ｐｔｙ Ｌｔｄ 感染症の技術分野における白血球補充
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
WO2024026200A1 (en) * 2022-07-27 2024-02-01 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025531018A (ja) 2022-09-14 2025-09-19 ビオグノシス アーゲー 薬物標的滞留時間を決定し、最適な薬物－標的候補を選択する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
US20090018108A1 (en) * 2005-12-14 2009-01-15 Galderma S.A. Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin
CN101707877A (zh) * 2007-06-13 2010-05-12 杰伊·普拉夫达 诊断与治疗氧化过激类病症的材料和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
RU2214398C2 (ru) * 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
CN1675154A (zh) * 2002-06-07 2005-09-28 科蒂科股份有限公司 抑制巨噬细胞移动抑制因子(mif)的细胞因子或生物活性的萘衍生物
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
EP1711197A4 (en) * 2003-12-23 2008-11-05 Musc Found For Res Dev METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS
WO2009154800A2 (en) * 2008-06-21 2009-12-23 Webb-Waring Institute Compositions and methods for treating lung disorders
CN102781461A (zh) * 2009-12-28 2012-11-14 N.V.佩里科恩有限责任公司 局部用酰基谷胱甘肽制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
US20090018108A1 (en) * 2005-12-14 2009-01-15 Galderma S.A. Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin
CN101707877A (zh) * 2007-06-13 2010-05-12 杰伊·普拉夫达 诊断与治疗氧化过激类病症的材料和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
代新华，张志利，王文萍: "α-硫辛酸降低糖尿病大鼠氧化应激及对肾脏的保护", 《当代医学》 *
甄真，等: "《传染病合理用药手册》", 30 June 2007, 军事医学科学出版社 *
胡佩珍，等: "《中西医结合内科治疗学》", 31 March 1996, 化学工业出版社 *
谷长平，等: "盐酸戊乙奎醚对感染性休克大鼠心肌抗氧化机制研究", 《潍坊医学院学报》 *

Also Published As

Publication number Publication date
WO2014008273A2 (en) 2014-01-09
AU2017206229A1 (en) 2017-08-03
AU2013286876B2 (en) 2017-04-20
EP2866565A2 (en) 2015-05-06
EP2866565A4 (en) 2016-04-13
JP6509112B2 (ja) 2019-05-08
AU2013286876A1 (en) 2015-02-26
CA2915793A1 (en) 2014-01-09
JP2015523364A (ja) 2015-08-13
WO2014008273A3 (en) 2014-02-27
US20150174160A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
ES2912306T3 (es) Tetratiomolibdato de bis-colina para el tratamiento de enfermedad de Wilson
BRPI0707277B1 (pt) Composição, uso da mesma,e , formulação famacêutica
JP2003524630A (ja) Ｎｏ基化合物で心肺疾病を処置する方法
AU2021200321A1 (en) ADO-Resistant Cysteamine Analogs And Uses Thereof
TW201605434A (zh) 使用半胱胺及其衍生物治療粒腺體疾病
CN104582490A (zh) 治疗、诊断和/或监测氧相关疾病进展的方法
Fläring et al. Temporal changes in whole-blood and plasma glutathione in ICU patients with multiple organ failure
MCLAURIN et al. Primary hyperoxaluria
JP2012107023A (ja) 治療用栄養組成物又は組合せ、及びそれらの使用方法
Garbin et al. Management of hyperkalemia and associated complications in a ferret (Mustela putorius furo) with urinary obstruction requiring surgery
Magdalan et al. Acute intranasal intoxication with mercuric chloride taken accidently instead of cocaine-A case report
MD3493849T2 (ro) Utilizare noua a N,N-bis-2-mercaptoetil izoftalamidă
Katar et al. Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication
Gupta et al. Cartap poisoning: an unusual poisoning in North India
RU2240808C1 (ru) Способ лечения диабетической нейропатии
RU2457198C1 (ru) Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью
Miño-Bernal et al. Normal anion gap metabolic acidosis secondary to topiramate intake: case report
RU2458054C1 (ru) Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью
RU2337368C1 (ru) Способ коррекции нарушений перекисного окисления липидов и антиоксидантной активности при стресс-реакции после операций на щитовидной железе
Kumar et al. Diabetic ketoacidosis–An atypical presentation with olanzapine toxicity
US20110237672A1 (en) Use of a cysteine-containing substance to increase the ventilatory activity and erythropoietin production
Sakhaee Medical management: uric acid and cystine stones
AU2014346703A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
UA15076U (en) Method for treating preclinical disorders of carbohydrate metabolism in patients with lung tuberculosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150429

WD01 Invention patent application deemed withdrawn after publication